Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.57 |
| ▸ | FLT1 | P17948 | 10/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.44 |
| ▸ | SYK | P43405 | 2/20 | 0.44 |
| ▸ | PLK4 | O00444 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.44 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | PAK4 | O96013 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | PRKCG | P05129 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7126927 | 0.84 | FLT1 (0.73) | EGFRFLT1KDR | |
| SCHEMBL7120775 | 0.83 | EGFR (0.60) | EGFRFLT1SYKKDR | |
| SCHEMBL7129261 | 0.82 | FLT1 (0.48) | EGFRFLT1SYKRETKDR | |
| SCHEMBL7126148 | 0.78 | FLT1 (0.43) | EGFRFLT1SYKLCKRET | |
| SCHEMBL7125165 | 0.77 | SYK (0.64) | EGFRFLT1SYK | |
| SCHEMBL7119056 | 0.73 | FLT1 (1.00) | EGFRFLT1RETKDRMKNK1 | |
| SCHEMBL7119392 | 0.72 | EGFR (0.62) | EGFRFLT1SYKKDR | |
| SCHEMBL7117897 | 0.72 | EGFR (0.76) | EGFRFLT1KDRPRKCD | |
| SCHEMBL7127649 | 0.71 | EGFR (0.58) | EGFRFLT1SYKKDR | |
| SCHEMBL7115466 | 0.70 | FLT1 (0.74) | EGFRFLT1CDK1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162795-A1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER INC. | 2003-08-28 | — | — | US | claimed |
| US-6492383-B1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER INC. | 2002-12-10 | — | — | US | claimed |
| US-20030162795-A1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER INC. | 2003-08-28 | — | — | US | disclosed |
| US-6492383-B1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER INC. | 2002-12-10 | — | — | US | disclosed |
| EP-1028964-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999024440-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162795-A1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | TYMP, DPYD, HPRT1 | EGFR 2961/4885FLT1 1043/4885ROCK2 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.